- Home
- ELEV vs RPID Comparison
ELEV vs RPID Comparison
Compare ELEV & RPID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELEV
- RPID
- Stock Information
- Founded
- ELEV 2019
- RPID 2006
- Country
- ELEV United States
- RPID United States
- Employees
- ELEV N/A
- RPID N/A
- Industry
- ELEV Biotechnology: Pharmaceutical Preparations
- RPID Medical Specialities
- Sector
- ELEV Health Care
- RPID Health Care
- Exchange
- ELEV Nasdaq
- RPID Nasdaq
- Market Cap
- ELEV 34.0M
- RPID 37.3M
- IPO Year
- ELEV 2021
- RPID 2021
- Fundamental
- Price
- ELEV $0.61
- RPID $1.11
- Analyst Decision
- ELEV Strong Buy
- RPID
- Analyst Count
- ELEV 5
- RPID 0
- Target Price
- ELEV $7.80
- RPID N/A
- AVG Volume (30 Days)
- ELEV 673.9K
- RPID 114.2K
- Earning Date
- ELEV 11-06-2024
- RPID 11-01-2024
- Dividend Yield
- ELEV N/A
- RPID N/A
- EPS Growth
- ELEV N/A
- RPID N/A
- EPS
- ELEV N/A
- RPID N/A
- Revenue
- ELEV N/A
- RPID $26,170,000.00
- Revenue This Year
- ELEV N/A
- RPID $24.34
- Revenue Next Year
- ELEV N/A
- RPID $19.49
- P/E Ratio
- ELEV N/A
- RPID N/A
- Revenue Growth
- ELEV N/A
- RPID 27.31
- 52 Week Low
- ELEV $0.44
- RPID $0.58
- 52 Week High
- ELEV $5.83
- RPID $1.34
- Technical
- Relative Strength Index (RSI)
- ELEV 51.53
- RPID 55.12
- Support Level
- ELEV $0.52
- RPID $1.01
- Resistance Level
- ELEV $0.70
- RPID $1.19
- Average True Range (ATR)
- ELEV 0.06
- RPID 0.11
- MACD
- ELEV 0.00
- RPID -0.02
- Stochastic Oscillator
- ELEV 41.81
- RPID 30.30
About ELEV Elevation Oncology Inc. Common stock
Elevation Oncology Inc is an oncology company focused on the development of targeted therapeutics for the treatment of cancer in genomically defined patient populations. Its lead program is focused on neuregulin-1, or NRG1, fusions, which are rare genomic alterations that have the potential to be therapeutically actionable through targeted HER3 inhibition.
About RPID Rapid Micro Biosystems Inc.
Rapid Micro Biosystems Inc is an life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company's flagship Growth Direct platform automates and modernizes the antiquated, manual microbial quality control (MQC) testing workflows used in the pharmaceutical manufacturing operations across the globe. It derives revenue from development, manufacturing, marketing and selling Systems and related LIMS connection software, consumables and services.